搜索结果


   AHR

靶点ID:TCMBANKGE001080


靶点别名:RP85; bHLHe76


靶点描述:aryl hydrocarbon receptor


染色体:7


染色体位置:7p21.1


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:348


OMIM_Link:600253


Ensembl_Link:ENSG00000106546


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000025 3',4',5,7-tetrahydroxyflavanol C15H10O7 C1=C(C=C(C=C1O)O)C2=C(C(=O)C3=CC(=CC(=C3O2)O)O)O
TCMBANKIN000091 cinnamtannin d1 C45H36O18 864.76 C1C(C(OC2=C1C(=CC(=C2C3C(C(OC4=C3C(=CC5=C4C6C(C(O5)(OC7=CC(=CC(=C67)O)O)C8=CC(=C(C=C8)O)O)O)O)C9=CC(=C(C=C9)O)O)O)O)O)C1=CC(=C(C=C1)O)O)O
TCMBANKIN019601 chrysol C1=CC=C2C(=C1)C=CC3=C2C=CC4=CC=CC=C43
TCMBANKIN025538 colchine (R/S)-Colchicine; MLS001181527; HMS3267B14; NE55304; I06-0591; CCG-46868; MCULE-7902106432; DTXSID20274387; ST056390; IAKHMKGGTNLKSZ-UHFFFAOYSA-N; 064T868; SMR000567246; KSC621O9T; HMS2875H17; C22H25NO6; CC0177; AC1Q5ODH; TR-031757; (+/-)-Colchicine; FT-0665155; Benzo[a]heptalen-9(5H)-one,7-acetamido-6,7-dihydro-1,2,3,10-tetramethoxy-; NCGC00094629-04; NCGC00094629-05; N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide #; Epitope ID:141498; Neuro_000002; AC-281; M205; BRD-A46684810-001-04-6; SCHEMBL675246; KB-295593; J-013744; BC216204; AB00830494-06; CHEBI:23359; Acetamide,N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]-; MFCD00078484; Colchine; N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0(2),]hexadeca-1(16),2(7),3,5,11,14-hexaen-10-yl}acetamide; CTK5C1799; NCGC00094629-03; N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-acetamide; 209810-38-8; N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide; Z1431321925; AKOS016374434; N-{3,4,5,14-TETRAMETHOXY-13-OXOTRICYCLO[9.5.0.0(2),?]HEXADECA-1(16),2,4,6,11,14-HEXAEN-10-YL}ACETAMIDE; AKOS003381878; MolPort-001-785-612; N-((7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7-trihydrobenzo[d]heptalen-7-yl)acetam ide; DB01394; NCGC00094629-01; NCGC00094629-06; AS-14691; 16416P; N-(1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl)acetamide; N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0;{2,7}]hexadeca-1(16),2(7),3,5,11,14-hexaen-10-yl}acetamide; BBL010108; N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0^{2,7}]hexadeca-1(16),2,4,6,11,14-hexaen-10-yl}acetamide; NCGC00094629-02; SBB079703; SR-01000636539-1; 54192-66-4; N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0?,?]hexadeca-1(16),2(7),3,5,11,14-hexaen-10-yl}acetamide; (S)-Colchicine >95%; STK801462; 1,2,3,10-Tetramethoxy-7-(acetylamino)-5,6,7,9-tetrahydrobenzo[a]heptalene-9-one; AC1L1EKN; CHEMBL87; N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7-trihydrobenzo[d]heptalen-7-yl)acetamide; KB-86571 C22H25NO6 399.4 g/mol CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
TCMBANKIN033660 2-Octynal 1846-68-0; 273643_ALDRICH; EINECS 217-427-5; Oct-2-ynal C8H12O 124.18 CCCCCC#CC=O
TCMBANKIN036819 alpinetin alpinetin C16H14O4 270.28 COC1=CC(=CC2=C1C(=O)CC(O2)C3=CC=CC=C3)O
TCMBANKIN037648 Lutein SMP1_000317; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol; SCHEMBL10029505; CHEBI:28838; NSC59193; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-1-cyclohex-2-enol; C08601; LMPR01070274; (1R,4R)-4-[18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-2-en-1-ol; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-cyclohex-2-en-1-ol; lutein; 127-40-2; Xanthophyll; (3R,3'R,6'R)-beta,epsilon-carotene-3,3'-diol; BCBcMAP01_000190; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol; (1R,4R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-1-cyclohex-2-enol C40H56O2 568.87 CC1=C(C(CC(C1)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2C(=CC(CC2(C)C)O)C)C)C
TCMBANKIN040211 Ginsenoside Rg1 ginsenosiderg1; ginsenoside r g1; sanchinoside C1; (20S)-3beta,12beta-Dihydroxy-4,4,8beta,14alpha-tetramethyl-6alpha,20-bis(beta-D-glucopyranosyloxy)-18-norcholestane-24-ene 801.01
TCMBANKIN041871 cyanidine-3-glucoside C9H15N3O6 261.232 C1([H])=NC([H])=NC([H])([H])N1O[C@@]2([H])O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]2([H])O[H]
TCMBANKIN046317 galangin 3,5,7-trihydroxy-2-phenyl-4-chromenone; NCGC00142457-01; ZINC00120273; 3,5,7-trihydroxy-2-phenyl-chromen-4-one; ST056288; ACon1_000977; AIDS-003058; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; 3,5,7-trihydroxy-2-phenyl-chromone; TNP00099; AIDS003058; 5-18-04-00567 (Beilstein Handbook Reference); MEGxp0_000533; NSC 407229; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; NCGC00017220-01; BRN 0272179; Norizalpinin; NSC407229; 282200_ALDRICH; Galangin; FLAVONE, 3,5,7-TRIHYDROXY-; C10044; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl- (9CI); EINECS 208-960-4; 3,5,7-trihydroxy-2-phenylchromen-4-one; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 548-83-4 C15H10O5 270.237 c1(O[H])c([H])c(OC(c2c([H])c([H])c([H])c([H])c2[H])=C(O[H])C3=O)c3c(O[H])c1[H]
TCMBANKIN057905 ferrum iron Fe 55.84 g/mol [Fe]
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058213 kaemferol;kampferol;kaempferol;campherol TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- C15H10O6 286.24 g/mol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
TCMBANKIN058310 cinnamaldehyde trans-Cinnamaldehyde, >=98%, FCC, FG; (E)-3-phenylacrolein; DSSTox_GSID_24834; 3-Phenyl-2-propenal; LS-378; UNII-SR60A3XG0F; (3E)-3-phenylprop-2-enal; Cinnamal; ZINC1532777; CS-0009609; (trans)-cinnamaldehyde; NSC-16935; NCGC00091512-02; NSC 16935; ST50213393; D0PJ3M; Aldehyd skoricovy; MolPort-004-288-292; Abion CA; BRN 1071571; 2-propenal, 3-phenyl-, (2E)-; trans-3-Phenylacrolein; FEMA No. 2286; transcinnamaldehyde; Cinnamaldehyde, trans-; Cinnamic aldehyde; DTXSID6024834; 3-Phenylpropenal; 3-Phenyl-2-propen-1-al; 3-phenylprop-2-enal; Cinnamaldehyde (trans), neat; AIDS-097032; BB_NC-2240; trans-Cinnamic aldehyde; NSC40346; TRANS-CINNAMALDEHYDE (SEE ALSO CINNAMALDEHYDE (104-55-2)); CCRIS 6222; trans-3-Phenyl-2-propenal; 3-Fenylpropenal [Czech]; CCRIS 3189; BBL010378; MLS002454394; SCHEMBL3441; NCGC00091512-05; ST5213393; AIDS097032; CNMA; CAS-14371-10-9; Zimtaldehyde; (2E)-3-phenylprop-2-enal; Cinnamaldehyde, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4; NCGC00259353-01; 2-Propenal, 3-phenyl-, (E)- (9CI); Cassia aldehyde; 3-Phenylacrylaldehyde; 3-Phenylacrolein; NCGC00257017-01; M181; SR60A3XG0F; W228605_ALDRICH; 14371-10-9; Hefty Dog and Cat Repellent; trans cinnamic aldehyde; (E)-Cinnamic aldehyde; NCI-C56111; NSC16935; BDBM50203065; 2-Propenal, 3-phenyl-; (2E)-3-phenylacrylaldehyde; AK-77787; A801001; trans-Cinnamaldehyde, >=99%; GTPL2423; CINNAMALDEHYDE (TRANS); AS-12078; Benzylideneacetaldehyde; Cinnamaldehyde [NF]; BRN 0605737; DB-003796; AC1LCUDE; 58840-EP2308879A1; trans-3-Phenylacrylaldehyde; 2-propenal,3-phenyl-,(E)-; NSC-40346; TR-001003; Tox21_111144; W228613_ALDRICH; 58840-EP2305682A1; STK397371; (2E)-3-Phenyl-2-propenal; KB-81236; NCGC00091512-06; C00903; cinnamaldehyde ; Cinnamaldehyde, (E)-; trans-Cinnamaldehyde, 99%; Tox21_201804; 2-Propenal, 3-phenyl-, (E)-; AK158901; AI3-00473; (E)-3-Phenyl-2-propenal; 104-55-2; MFCD00007000; 96320_FLUKA; R501736; ST24024694; (E)-3-phenyl-acrylaldehyde; 239968_ALDRICH; AJ-26812; Phenylacrolein; trans-Cinnamaldehyde; Aldehyd skoricovy [Czech]; ST2407775; W-205597; Cinnamylaldehyde; LS-850; EINECS 203-213-9; AC1Q6PPL; RL00215; ZINC01532777; ACN-035400; bmse010257; 4-07-00-00984 (Beilstein Handbook Reference); C9H8O; (E)-3-Phenyl-propenal; trans-Cinnamaldehyde, analytical standard; Cinnamic aldehyde (natural); NCGC00091512-07; trans-Cinnamylaldehyde; Tox21_303271; EC 203-213-9; C80687_ALDRICH; EPA Pesticide Chemical Code 040506; Cinnamyl aldehyde; RTR-001003; SMR000112334; AN-24684; beta-phenylacrolein; cinnamic aldehyde, (E)-isomer; CHEBI:16731; WLN: VH1U1R; I14-109742; (E)-3-phenylacrylaldehyde; RT-001454; I14-7336; 2-07-00-00273 (Beilstein Handbook Reference); Epitope ID:150921; trans-Cinnamaldehyde; trans-3-Phenylacrylaldehyde; NCGC00091512-01; DSSTox_RID_77548; AC1Q6BJW; trans cinnamaldehyde; CHEMBL293492; SBB028652; (E)-3-phenyl-2-propenal(E)-cinnamaldehyde; 3-Fenylpropenal; (E)-phenylvinyl aldehyde; trans-Cinmaldehyde; KJPRLNWUNMBNBZ-QPJJXVBHSA-N; Nat. Cinnamaldehyde; (E)-Cinnamaldehyde; NATURAL CINNAMIC ALDEHYDE; FEMA Number 2286; HMS2268O08; AKOS000119171; Cinnemaldehyde; beta-Phenylcrolein; SC-19143; HSDB 209; B99DD6C7-1C6D-4FE3-A172-54BFDB987683; 3-PHENYL-2-PROPENAL (TRANS); CINNAMALDEHYDE; Cinnamaldehyde, Vetec(TM) reagent grade, 93%; AI3-33275; NCGC00091512-04; e-cinnamaldehyde; Cinnamaldehyde, natural, >=95%, FG; (E)-3-phenylprop-2-enal; Acrolein, 3-phenyl-; AM20060482; BG01497386; 3-Phenyl-2-propenaldehyde; N1482; Cinnamaldehyde, 95% 100g; KB-76097; Caswell No. 221A; CINNAMALDEHYDE (SEE ALSO TRANS-CINNAMALDEHYDE (14371-10-9)); CJ-24256; DSSTox_CID_4834; MolPort-000-871-213; (E)-3-Phenylpropenal; Cinnamaldehyde, Natural; Trans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenalTrans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenal C9H8O 132.16 C1=CC=C(C=C1)C=CC=O
TCMBANKIN058367 indirubin NSC-105327; KBio2_000450; 2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; 2-(2-oxo-3-indolinylidene)-3-indolinone; Couroupitine B; [.DELTA.2,3'-Biindoline]-2',3-dione; MLS000759416; 479-41-4; 5-24-08-00507 (Beilstein Handbook Reference); KBio3_000839; NSC105327; NSC 105327; (2E)-2-(2-ketoindolin-3-ylidene)pseudoindoxyl; KBioGR_000450; Indigopurpurin; KBioSS_000450; (2E)-2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; indirubin ; (delta2,3'-Biindoline)-2',3-dione (8CI); 2-(2-ketoindolin-3-ylidene)pseudoindoxyl; (delta(sup 2,3')-BIINDOLINE)-2',3-DIONE; Indirubin; (2E)-2-(2-oxoindolin-3-ylidene)indolin-3-one; 2H-Indol-2-one, 3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-; SMR000466311; 2H-Indol-2-one, 3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro- (9CI); BRN 0088279; C.I. 73200; KBio2_005586; (2E)-2-(2-oxo-3-indolinylidene)-3-indolinone; Indigo Red; KBio2_003018; EM-A05-INDIRUBIN; 2-(2-oxoindolin-3-ylidene)indolin-3-one; KBio3_000840; Bio2_000395; Bio2_000875; (2Z)-2-(2-oxo-3-indolinylidene)-3-indolinone; (2Z)-2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; IDI1_002150; BSPBio_001110; NCGC00163356-01; BiomolKI2_000073; NCGC00163356-02; NCGC00163356-03; BiomolKI_000069; (2Z)-2-(2-ketoindolin-3-ylidene)pseudoindoxyl; (2Z)-2-(2-oxoindolin-3-ylidene)indolin-3-one C16H10N2O2 262.26 C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O
TCMBANKIN058381 4-hydroxy-2-quinolinecarboxylic acid kynurenic acid; KYNA C10H7NO3 189.17 g/mol C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O
TCMBANKIN058409 anthracene J-200085; WLN: L C666J; AN-10591; A804437; Bis-alkylamino anthracene; Anthrazen; Anthracene, ReagentPlus(R), 99%; I14-0862; Anthracene, sublimed grade, >=99%; InChI=1/C14H10/c1-2-6-12-10-14-8-4-3-7-13(14)9-11(12)5-1/h1-10; 40076_SUPELCO; NCGC00254204-01; acene; AC1L1QYH; Green Oil; Anthracene solution, certified reference material, 1000 mug/mL in acetone; Anthracene 10 microg/mL in Cyclohexane; ANTHRACENE- D10; Tetraoliven2G; Anthracen; Anthracene, zone-refined, >=99%; polyacenes; NCGC00163972-03; DSSTox_CID_3878; Anthracene, analytical standard; Anthracene, certified reference material, TraceCERT(R); SBB058663; MFCD00001240; TR-003345; Paranaphthalene; 141062_SIAL; Sterilite hop defoliant; PubChem22168; Tox21_300014; acenes; SC-47157; BBL005251; (9,10-Dihydroanthracene-9,10-diyl); NCGC00259775-01; Azen; KSC174Q2B; Anthracene, reagent grade, 97%; Coal tar pitch volatiles: anthracene; Tox21_202226; 48567_SUPELCO; AJ-27544; 54261-80-2; F0001-0328; UNII-EH46A1TLD7; H2412; NSC7958; CTK0H4820; C14315; CAS-120-12-7; HRACENE; Anthracene solution, certified reference material, 200 mug/mL in methanol; 331481_ALDRICH; EC 204-371-1; BDBM50060894; Anthracin; A0992; STK398386; EINECS 204-371-1; RP23973; p-Naphthalene; ZINC1586329; AC-5799; AI3-00155; MCULE-4141881437; DSSTox_RID_77216; CCRIS 767; 2-anthryl; 48647_SUPELCO; CHEMBL333179; RTR-003345; Anthracene, labeled with deuterium; L975; Epitope ID:119716; 1-anthryl; NCGC00163972-02; ACMC-1C338; TL8000534; 120-12-7; Paranaphtalene; AB1002596; anthracen-9-yl; 46051_RIEDEL; A0405; ST093055; FT-0622409; Anthracene 10 microg/mL in Acetonitrile; Anthracen [German]; Anthracene, vial of 250 mg, analytical standard; J3.643.785E; MWPLVEDNUUSJAV-UHFFFAOYSA-N; ANW-17457; Anthracene oil; DTXSID0023878; Tetra Olive N2G; ANTHRACENE, SCINTILLATOR; 10580_FLUKA; CHEBI:35298; NCGC00163972-01; DSSTox_GSID_23878; Deuterated anthracene; Acen; MolPort-001-760-592; Anthracene, puriss., 99.0%; 27735-76-8; ST24045970; CHEBI:35297; Anthracene 100 microg/mL in Acetonitrile; Anthracene, suitable for scintillation, >=99.0% (GC); Anthracene, pure; AK157086; ANTHRACENE; A89200_ALDRICH; AN3; Anthraxcene; AS-14635; UNII-0TNN3Q0D4D component MWPLVEDNUUSJAV-UHFFFAOYSA-N; NSC 7958; A0495; KB-74701; Anthracene oil (coal tar fraction); LS-627; Coal tar pitch volatiles:anthracene; AKOS000119970; HSDB 702; 61062-81-5; EH46A1TLD7; 27735-77-9; KS-00000UYL; NSC-7958; Green Oil; AI3-00155; 48647_SUPELCO; CCRIS 767; Anthrazen; InChI=1/C14H10/c1-2-6-12-10-14-8-4-3-7-13(14)9-11(12)5-1/h1-10; Coal tar pitch volatiles: anthracene; 40076_SUPELCO; 48567_SUPELCO; Anthracene, pure; ANTHRACENE; A89200_ALDRICH; paranaphthalene, anthracin, anthraxcene, green oil, tetra olive n2g; c0991; AN3; 120-12-7; 46051_RIEDEL; NSC7958; Anthracene solution; NSC 7958; Anthracene oil (coal tar fraction); Anthracen [German]; Anthracen; C14315; HSDB 702; 331481_ALDRICH; Paranaphthalene; Tetra Olive N2G; Anthracin; 141062_SIAL; 10580_FLUKA; CHEBI:35298; EINECS 204-371-1; NCGC00163972-01 C14H10 178.23 C1=CC=C2C=C3C=CC=CC3=CC2=C1
TCMBANKIN058629 rutacarpine rutaecarpine;rutecarpine C18H13N3O 287.3 g/mol C1CN2C(=NC3=CC=CC=C3C2=O)C4=C1C5=CC=CC=C5N4
TCMBANKIN058846 bergamotin 380B407; MFCD00017409; SCHEMBL569529; BDBM50310823; AK689401; Bergamotin; Bergomottin; ZINC1658570; NCGC00161832-01; Bergamottin, analytical standard; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-((3,7-dimethyl-2,6-octadienyl)oxy)-, (E)-; JMU611YFRB; C-20280; B3943; Bergamottin; UNII-JMU611YFRB; AC1NV7JD; 7380-40-7; CHEMBL1078442; 5-Geranoxypsoralen; AKOS000277132; 5-Geranyloxypsoralen; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-[[(2E)-3,7-dimethyl-2,6-octadien-1-yl]oxy]-; TNP00285; NCGC00017345-01; 4-([(2E)-3,7-dimethyl-2,6-octadienyl]oxy)-7h-furo[3,2-g]chromen-7-one; DBMJZOMNXBSRED-OQLLNIDSSA-N; CCRIS 8085; CHEBI:70476; MolPort-044-724-380; Bergamotine; 4-[(2E)-3,7-dimethylocta-2,6-dienoxy]furo[3,2-g]chromen-7-one; CJ-26818; Bergaptin; Ambotz7380-40-7; 4-{[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]oxy}-7H-furo[3,2-g]chromen-7-one; NSC710599; NSC-710599; SCHEMBL7183139; MolPort-000-881-227 C21H22O4 338.4 g/mol CC(=CCCC(=CCOC1=C2C=CC(=O)OC2=CC3=C1C=CO3)C)C
TCMBANKIN058867 ginsenoside rb1 Q-100470; A-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl ; GRb 1; MFCD00133367; ginsenosiderb1; Ginsenoside-Rb1 from Panax ginseng (Korean ginseng) root, triterpenoid saponin; beta-D-Glucopyranoside, (3-beta,12-beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-; N1620; NSC 310103; CHEBI:67989; Ginsenoside Rb1, primary pharmaceutical reference standard; C20713; Panax saponin E; 7413S0WMH6; Pseudoginsenoside D; 87700-07-0; A-Glucopyranosyl-(3; C54H92O23; A)-20-[(6-O-; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl-beta-D-glucopyranoside; Ginsenoside Rb1, European Pharmacopoeia (EP) Reference Standard; (3beta,12beta)-20-{[6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl]oxy}-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; 20(S)-ginsenoside Rb1; 2-O-; Ginsenoside Rb1 (saponin of panax ginseng); 52286-61-0; 12770-17-1; 393829-67-9; CS-3829; BIDD:ER0108; A,12; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl beta-D-glucopyranoside; GZYPWOGIYAIIPV-JBDTYSNRSA-N; Ginsenoside-Rb1 from Panax ginseng (Korean ginseng) root; GS-Rb1; 41753-43-9; ginsenoside-rb1; ginsenoside r b1; 212055-66-8; UNII-7413S0WMH6; AB0016710; AKOS025311537; A-D-glucopyranoside; Ginsenoside rb1; MolPort-016-638-397; gensenoside Rb1; Gypenoside III; ginsenoside Rb1; CHEMBL501515; HY-N0039; Gynosaponin C; BDBM50317541; (3beta,12beta)-20-[(6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; Ambap41753-43-9; GSRb1; Ginsenoside-Rb1; 753G439; Sanchinoside E1; A-D-glucopyranosyl-; Panaxsaponin E; O899; ginsenoside-Rb1;gypenosideIII C54H92O23 1109.3 g/mol CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C
TCMBANKIN059438 2-methoxy-4-propenyl phenol C10H12O2 164.2 g/mol CC=CC1=CC(=C(C=C1)O)OC
TCMBANKIN059684 Vitamin E β- C29H50O2 430.79 CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746 α-tocopherol C29H50O2 430.7 g/mol CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
TCMBANKIN061674 palmatin;palmatine V1557; 5,6-Dihydro-2,3,9,10-tetramethoxydibenzo(a,g)quinolizinium hydroxide; Calystigine; Palmatine chloride; palmatine ; 6771L5MN8S; UNII-6771L5MN8S; MolPort-039-138-801; 3486-67-7 (Parent); Palmatine hydroxide; 131-04-4; BG01657711; AC1L43OM; Palmatinium hydroxide; LS-61262; DTXSID60156830; 7,8,13,13a-Tetradehydro-2,3,9,10-tetramethoxyberbinium hydroxide; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-, hydroxide; 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium hydroxide; AS-17724 C21H22NO4+ 352.4 g/mol COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC
TCMBANKIN061675 berberime berberine ; isoquinoline alkaloid; berberine C20H18NO4+ 336.4 g/mol COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI001965 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI002466 Infections - Disease or Syndrome disease
TCMBANKDI002512 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI002718 - - Finding phenotype
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI003411 - - Disease or Syndrome disease
TCMBANKDI003879 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases Abnormality of the genitourinary system Congenital Abnormality disease
TCMBANKDI004086 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI004145 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction group
TCMBANKDI004666 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases; Nervous System Diseases Abnormality of the eye Congenital Abnormality disease
TCMBANKDI005318 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI005539 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases - Neoplastic Process disease
TCMBANKDI005542 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process group
TCMBANKDI006084 Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI006154 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI006612 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI006900 - Abnormality of head or neck Finding phenotype
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007110 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system Congenital Abnormality disease
TCMBANKDI007228 - - Finding phenotype
TCMBANKDI007737 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI009080 Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases Abnormality of the integument; Abnormality of head or neck Disease or Syndrome disease
TCMBANKDI009470 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI009521 - - Sign or Symptom phenotype
TCMBANKDI009657 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality group
TCMBANKDI009722 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI009827 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Respiratory Tract Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases Abnormality of head or neck Congenital Abnormality disease
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI010048 Infections; Respiratory Tract Diseases Abnormality of the immune system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI010239 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI011083 Pathological Conditions, Signs and Symptoms - Sign or Symptom group
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011419 Neoplasms - Neoplastic Process disease
TCMBANKDI011458 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI011496 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI011608 Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012064 Immune System Diseases - Disease or Syndrome phenotype
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI012078 Pathological Conditions, Signs and Symptoms; Infections; Musculoskeletal Diseases - Disease or Syndrome group
TCMBANKDI012424 Pathological Conditions, Signs and Symptoms; Neoplasms - Pathologic Function phenotype
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013148 Respiratory Tract Diseases; Nervous System Diseases Abnormality of the nervous system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI013541 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI014740 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome phenotype
TCMBANKDI015238 Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015757 Infections - Disease or Syndrome disease
TCMBANKDI016050 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI016459 - - Neoplastic Process disease
TCMBANKDI016800 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017474 - - Disease or Syndrome disease
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI017915 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases Abnormality of the endocrine system; Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI017965 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Finding phenotype
TCMBANKDI018635 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018761 - - Diagnostic Procedure phenotype
TCMBANKDI018854 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI018992 Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI019869 Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI020257 Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI020451 Neoplasms - Neoplastic Process disease
TCMBANKDI020602 Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI020603 Pathological Conditions, Signs and Symptoms - Anatomical Abnormality phenotype
TCMBANKDI021285 Neoplasms Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI021339 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome group
TCMBANKDI021345 Digestive System Diseases; Infections - Disease or Syndrome disease
TCMBANKDI022361 Pathological Conditions, Signs and Symptoms; Eye Diseases - Sign or Symptom phenotype
TCMBANKDI023140 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI024561 - - Neoplastic Process disease
TCMBANKDI024839 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026029 - - Disease or Syndrome disease
TCMBANKDI027026 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI027211 Immune System Diseases - Disease or Syndrome disease
TCMBANKDI028561 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI028640 Neoplasms - Neoplastic Process disease
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI028908 Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases Abnormality of the eye Disease or Syndrome phenotype
TCMBANKDI029520 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI030527 - - Sign or Symptom phenotype
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI030870 Neoplasms - Neoplastic Process disease
TCMBANKDI031139 Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031912 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI032189 Respiratory Tract Diseases; Wounds and Injuries - Disease or Syndrome disease
TCMBANKDI032222 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI032496 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease